MediciNova Announces MN-166 (ibudilast) Demonstrated a 26% Reduction in Confirmed Disability Progression

MediciNova, a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), announced the presentation of additional positive clinical data from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS), which was conducted through the National Institutes of Health-sponsored NeuroNEXT network.

As quoted in the press release:

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc. commented, “We are extremely pleased with these results.  Ibudilast’s magnitude of reduction in disability progression was better than the data reported for the only drug approved for progressive MS and also better than the data reported for the other drugs being developed for progressive MS.  With a convenient oral administration, a very favorable safety and tolerability profile compared to other MS drugs, and potentially better efficacy than any other drug for progressive MS, we believe ibudilast is well positioned to become the best-in-disease drug. As a next step, we plan to get formal feedback from FDA so we can move this program forward as fast as possible.”

Click here to read the full press release.